Estrogen receptors: Bioactivities and interactions with cell signaling pathways

Biology of Reproduction

Volumn 54, Issue 2, 1996, Pages 287-293

  Katzenellenbogen, Benita S ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ENZYME ACTIVATOR; ESTROGEN; ESTROGEN RECEPTOR; GROWTH FACTOR; PROGESTERONE RECEPTOR; PROTEIN KINASE;

ARTICLE; CELL; CELL SPECIFICITY; GENE EXPRESSION REGULATION; HORMONE BINDING; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030031782     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod54.2.287     Document Type: Article

References (74)

1. Beato M Gene regulation by steroid hormones Cell 1989; 56 335-344.
2. Evans HM The steroid and thyroid hormone receptor superfamily. Science 1988; 240.889-895
3. Carson-Jurica MA, Schrader W, O'Malley B Steroid receptor family: structure and functions Endocr Rev 1990, 11:201-220.
4. Tsai MJ, O'Malley BW Molecular mechanisms of action of steroid/thyroid receptor superfamily members Annu Rev Biochem 1994, 63.451-486
5. Green S, Chambon P, The oestrogen receptor from perception to mechanism In: Parker M (ed ), Nuclear Hormone Receptors. New York: Academic Press, 1991:15-38.
6. Ryffel GU, Klein-Hitpass L, Druege P, Doebbeling U, Heitlinger E, Cato AC The estrogen-responsive DNA-element, structure and interaction with the estrogen receptor J Steroid Biochem 1988; 35:219-222.
7. Kumar V, Chambon P. The estrogen receptor binds rightly to its responsive element as a ligand-induced homodimer. Cell 1988, 55:145-156.
8. Truss M, Beato M. Steroid hormone receptors: interaction with deoxyribonucleic add and transcription factors Endocr Rev 1993, 14 459-479.
9. Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 1987, 8.29-43
10. Lippman ME, Dickson RB, Gelmann EP, Knabbe C, Jasid K, Bates S, Swain S. Mechanisms of estrogenic and antiestrogenic regulation of growth of human breast carcinoma In Klijn JGM (ed.), Hormonal Manipulation of Cancer Peptides, Growth Factors, and New (anti)Steroidal Agents New York: Raven Press, 1987: 381-403.
11. Katzenellenbogen BS, Bhakoo, HS, Ferguson ER, Lan NC, Tatee T, Tsai TL, Katzenellenbogen JA. Estrogen and antiestrogen action in reproductive tissues and tumors Recent Prog Horm Res 1979, 35:259-300
12. Katzenellenbogen BS. Dynamics of steroid hormone receptor action Annu Review Physiol 1980; 42:17-35
13. Read LD, Katzenellenbogen BS. Characterization and regulation of estrogen and progesterone receptors in breast cancer. In Dickson RB, Lippman ME (eds ), Genes, Oncogenes and Hormones. Advances in Cellular and Molecular Biology of Breast Cancer. Nowell, MA. Kluwer-Nijhoff Publishers; 1991. 277-299
14. Sarrel PM, Lufkin EG, Oursler MJ, Keefe D. Estrogen actions in arteries, bone and brain Sci Am Sci Med 1994; 1.44-53
15. Kneifel MA, Katzenellenbogen BS. Comparative effects of estrogen and antiestrogen on plasma renin substrate levels and hepatic estrogen receptors in the rat. Endocrinology 1981; 108.545-552.
16. Toney TW, Katzenellenbogen BS Antiestrogen action in the medial basal hypothalamus and pituitary of immature female rats, insights concerning relationships among estrogen, dopamine and prolactin. Endocrinology 1986, 119:2661-2669.
17. Berry M, Metzger D, Chambon P Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen EMBO J 1990, 9.2811-2818.
18. Montano MM, Muller V, Trobaugh A, Katzenellenbogen BS The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 1995, 9:814-825.
19. Fujimoto N, Katzenellenbogen BS Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen-selectivity and promoter-dependence. Mol Endocrinol 1994, 8:296-304.
20. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW. McDonnell DP Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions Mol Endocrinol 1994; 9.21-30.
21. Katzenellenbogen BS, Miller RA, Mullick A, Sheen YY Antiestrogen action in breast cancer cells modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites Breast Cancer Res Treat 1985, 5:231-243
22. Jordan VC, Murphy CS Endocrine pharmacology of antiestrogens as antitumor agents Endocr Rev 1990, 11:578-610
23. Santen R, Manni A, Harvey H, Redmond C Endocrine treatment of breast cancer in women. Endocr Rev 1990, 11.221-265.
24. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987, 47 4355-4360
25. Katzenellenbogen BS Antiestrogen resistance mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy J Natl Cancer Inst 1991, 83 1434-1435
26. Wrenn CK, Katzenellenbogen BS Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J Biol Chem 1993 268.24089-24098.
27. Ince BA, Zhuang Y, Wrenn CK, Shapiro DJ, Katzenellenbogen BS Powerful dominant negative mutants of the human estrogen receptor J Biol Chem 1993; 268.14026-14032
28. Ince BA, Schodin DJ, Shapiro DJ, Katzenellenbogen BS. Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors. Endocrinology 1995; 136.3194-3199.
29. Pakdel F, Katzenellenbogen BS Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. J Biol Chem 1992; 267:3429-3437
30. Pakdel F, Reese JC, Katzenellenbogen BS Identification of charged residues in an N-terminal portion of the hormone binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol Endocrinol 1993; 7.1408-1417
31. Katzenellenbogen BS, Bhardwaj B, Fang H, Ince BA, Pakdel F, Reese JC, Schodin DJ, Wrenn CK Hormone binding and tianscripcion activation by estrogen receptors: analyses using mammalian and yeast systems J Steroid Biochem Mol Biol 1993, 47:39-48
32. Harlow KW, Smith DN, Katzenellenbogen JA, Greene GL, Katzenellenbogen BS. Identification of cysteine-530 as the covalent attachment site of an affinity labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor J Biol Chem 1989; 264 17476-17485.
33. Danielian PS, White R, Hoare SA, Fawell SF, Parker MG Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen Mol Endocrinol 1993, 7:232-240.
34. Danielian PS, White R, Lees JA, Parker MG Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors EMBO J 1992, 11.1025-1033.
35. Reese JC, Katzenellenbogen BS. Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation J Biol Chem 1992, 267:9868-9373
36. Aronica SM, Katzenellenbogen BS. Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3′,5′-monophosphate and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors Endocrinology 1991; 128.2045-2052
37. Aronica SM, Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 1993; 7 743-752.
38. Cho H, Katzenellenbogen BS Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators Mol Endocrinol 1993; 7:441-452.
39. Katzenellenbogen BS, Norman MJ Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology 1990; 126:891-898
40. Cho H, Aronica SM, Katzenellenbogen BS. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells a comparison of the effects of cyclic AMP, estradiol, IGF-1 and serum factors. Endocrinology 1994; 134 658-664
41. Reese JK, Katzenellenbogen BS Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells Nucleic Acids Res 1991, 19:6595-6602
42. Reese JC, Katzenellenbogen BS Examination of the DNA binding abilities of estrogen receptor in whole cells implications for hormone-independent transactivation and the action of the pure antiestrogen ICI164,384. Mol Cell Biol 1992, 12:4531-4538.
43. Freiss G, Vignon F Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Mol Endocrinol 1994, 8:1389-1396.
44. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992; 89 4037-4041
45. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICE164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990; 87:6883-6887.
46. Fawell SE, Lees JA, White R, Parker MG. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 1990, 60.953-962
47. Angel P, Imagawa M, Chiu M, Stein B, Imbra RJ, Rahmsdorf HJ, Jonat C, Herrlich P, Karin M Phorbol ester-inducible genes contain a common cis-acting element recognized by a TPA-modulator trans-acting factor Cell 1987, 49:729-739
48. Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, Verma LM, Evans RM. Functional antagonism between oncoprotein c-jun and the glucocorticoid receptor Cell 1990 62 1217-1226
49. Yang-Yen H, Chambard J, Sun Y, Smeal T, Schmidt TJ, Drouin J, Karin M Transcriptional interference between c-jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction Cell 1990; 62 1205-1215.
50. Gaub M, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex Cell 1990, 53:1267-1276
51. Shemshedini L. Knauthe R, Sassone-Corsi P, Pornon A, Gronemeyer H Cell-specific inhibitory and stimulatory effects of fos and jun on transcription activation by nuclear receptors EMBO J 1991; 10 3839-3849.
52. Strahle U, Schmid W, Schütz G. Synergistic action of the glucocorticoid receptor with transcription factors. EMBO J 1988; 7:3389-3395.
53. Sumida C, Lecerf F, Pasqualini JR Control of progesterone receptors in fetal uterine cells in culture: effects of estradiol, progestins, antiestrogens, and growth factors. Endocrinology 1988; 122:3-11
54. Sumida C, Pasqualini JR. Stimulation of progesterone receptors by phorbol ester and cyclic AMP in fetal uterine cells in culture. Mol Cell Endocrinol 1990, 69 207-215
55. Sumida C, Pasqualini JR. Antiestrogen antagonizes the stimulatory effect of epidermal growth factor on the induction of progesterone receptor in fetal uterine cells in culture Endocrinology 1989; 124.591-597
56. Kraus WL, Montano MM, Katzenellenbogen BS. Cloning of the rat progesterone receptor gene 5′ region and identification of two functionally distinct promoters Mol Endocrinol 1993, 7 1603-1616.
57. Gottardis MM, Jordan VC Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988; 48:5183-5187.
58. Groul DJ, Altschmeid J. Synergistic induction of apoptosis with glucocorticoids and 3′,5′-cyclic adenosine monophosphate reveals agonist activity by RU486 Mol Endocrinol 1993; 7:104-113.
59. Sartorius CA, Tung L, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP J Biol Chem 1993; 268:9262-9266.
60. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways Proc Natl Sci Acad USA 1993; 90:4441-4445.
61. Ali S, Metzger D, Bornert J-M, Chambon P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region EMBO J 1993; 12 1153-1160.
62. Denton RR, Koszewski NJ, Notides AC Estrogen receptor phosphorylation: hormonal dependence and consequence on specific DNA binding. J Biol Chem 1992; 267.7263-7268.
63. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS Phosphorylation of the human estrogen receptor identification of hormone-regulated sites and examination of their influence on transcriptional activity J Biol Chem 1994; 269:4458-4466
64. Lahooti H, White K, Danielian PS, Parker MG Characterization of ligand-dependent phosphorylation of the estrogen receptor. Mol Endocrinol 1994, 8:182-188
65. Arnold SF, Obourn JD, Jaffe H, Notides AC Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol 1994; 8.1208-1214.
66. Castoria G, Migliaccio A, Green S, Di Domenico M, Chambon P, Auricchio F Properties of a purified estradiol-dependent calf uterus tyrosine kmase. Biochemistry 1993. 32 1740-1750.
67. Kraus WL, Katzenellenbogen BS. Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists Endocrinology 1993; 132:2371-2379
68. Kraus WL, Weis KE, Katzenellenbogen BS. Inhibitory cross-talk between steroid hormone receptors differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol 1995, 15.1847-1857.
69. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding two functionally different human progesterone receptor forms A and B. EMBO J 1990, 9:1603-1614
70. Tora L, Gronemeyer H, Turcotte B, Gaub MP, Chambon P. The N-terminal region of the chicken progesterone receptor specifies target gene activation Nature 1988; 333:185-188.
71. Vegeto E, Shahbaz MM, Wen D X, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell- and promoter specific repressor of human progesterone receptor B function. Mol Endocrinol 1993, 7.1244-1255.
72. Levine M, Manley JL. Transcriptional repression of eukaryotic promoters. Cell 1989, 59 405-408.
73. McDonnell DP, Goldman ME. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism J Biol Chem 1994, 269:11945-11949.
74. Tung LT, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors Mol Endocrinol 1993, 7.1256-1265